New Skin Drug Shows Lasting Symptom Relief

Incyte announced promising long-term results for its experimental drug, povorcitinib, in treating moderate to severe hidradenitis suppurativa. This chronic skin condition causes painful lumps, abscesses, and scarring, predominantly in areas like the armpits and groin.

Data presented from two late-stage trials revealed that after 54 weeks of treatment, a significant portion of patients experienced substantial symptom relief. Up to 71.4% of participants achieved at least a 50% reduction in abscesses and inflamed skin bumps. Furthermore, major symptom reduction was observed in up to 57% of patients, with complete clearance of key skin lesions noted in up to 29% of participants.

Povorcitinib, a once-daily oral medication, targets inflammation by blocking the JAK1 protein. This mechanism offers a novel approach, as current treatment options are predominantly injectable drugs. The U.S. Food and Drug Administration and the European Medicines Agency are currently reviewing applications for povorcitinib's approval, potentially introducing a new therapeutic avenue for the estimated 1% to 4% of people affected by hidradenitis suppurativa in the United States.

The most frequently reported side effects during the trials included acne, nasopharyngitis, and upper respiratory tract infections. Hidradenitis suppurativa disproportionately impacts individuals from racial and ethnic minority groups. The drug's potential to offer significant symptom reduction marks a critical development for patients with limited treatment choices.